# Seroquel in Bipolar Depression Versus Lithium

> **NCT00206141** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 672 (—)

## Conditions studied

- Bipolar Disorder
- Bipolar Depression
- Depression

## Interventions

- **DRUG:** Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)

## Key facts

- **NCT ID:** NCT00206141
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 672 (—)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206141, "Seroquel in Bipolar Depression Versus Lithium". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00206141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*